Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
Annals of Oncology, 11/06/2009
Ennishi D et al. – A recent laboratory study indicated that statins impaired the antitumor effects of rituximab by inducing conformational changes in CD20. Although these findings ... about statin use during rituximab treatment, their clinical significance is unclear. The results of this study indicate that statins do not influence the clinical prognosis of DLBCL treated with RCHOP. Methods- Retrospective study investigating effects of statins on prognosis ... taking statins
Results- 3-year PFS rates 84% and 73% , while the overall survival rates were 89% and 78% for those patients treated with and without statins, respectively
- After adjusting for International Prognostic Index and serum cholesterol level, statin use is
[more...]
|
Statin therapy initiated in a man with hepatitis C and elevated cholesterol
The Clinical Advisor, 10/07/2009
|
Friedrich DA – Coronary atherosclerosis is a major cause of morbidity and mortality in Western society. Deposition of cholesterol in arterial walls is central to the pathogenesis of the disease. Based on extensive ... from statins is extremely rare, mild increases in liver enzymes can occur in 1%–3% of patients. Because of concerns about possible liver damage, statins are contraindicated in patients with liver disease. In Mr. F's case, the benefit of statin therapy outweighed the risk. Statin treatment is ... essential to reduce the profound morbidity and mortality associated with FH. Current studies have looked at the safety of statins in patients with established liver disease and suggested that these medications are safe (perhaps even beneficial) in patients with compensated liver disease
[more...]
|
Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/2009
|
2 trials that suggested lower target lipid levels were more often achieved with statin–ezetimibe combination therapy than with high–dose statin monotherapy. No firm trial evidence showed that combining a statin with another agent (bile–acid sequestrant, fibrate, ezetimibe, niacin, or ... stroke, or mortality) more often than high–dose statin monotherapy.
[more...]
|
Statins show dramatic drug and cell dependent effects in the brain
EurekAlert, 10/29/2009
|
Besides their tremendous value in treating high cholesterol and lowering the risk of heart disease, statins have also been reported to potentially lower the risks of other diseases, such as dementia. A study finds that similar ... statin drugs can have profoundly different effects on brain cells –both beneficial and detrimental. These findings reinforce the idea that great care should be taken when deciding on the dosage and type of statin given to individuals, particularly the elderly.
[more...]
|
Skeletal muscle cell MHC I expression: Implications for statin-induced myopathy
Muscle & Nerve, 10/12/2009
|
Singh P et al. – Statins potentiated the MHC I–inducing effect of IFN–gamma in TE671, but not in SKMC, neither at the protein level nor at the mRNA level. The increased muscle MHC I expression in statin–induced myopathy might not be ... by statins themselves.
[more...]
|
Are High-Risk Hypertensive Patients being Prescribed Concomitant Statin Therapy?: A Retrospective Cohort Study
American Journal of Cardiovascular Drugs, 10/07/2009
|
Chapman RH et al. – Among patients beginning antihypertensive treatment, those with established CHD or CHD risk factors were more likely to receive statins, but a substantial fraction did not fill any statin prescription. The ... statin therapy could benefit many hypertensive patients with additional CHD risk factors.
[more...]
|
Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence
Journal of Nephrology, 10/05/2009
|
Kanbay M et al. – It seems that statins have renoprotective effects in the early CKD stages, and encouragingly, safety and tolerability of statins are no more a problem than in non ... ndash;CKD patient cohorts. Statins seem to possess nephroprotective and cardioprotective properties which should be of great benefit to patients at risk of, or with, CKD.
[more...]
|
Statin prophylaxis and inflammatory mediators following cardiopulmonary bypass: a systematic review
Critical Care, 10/27/2009
|
Morgan C et al. – Although the RCT evidence may suggest a reduction in post–CPB inflammation by statin therapy, the evidence is not definitive due to significant limitations. Several of ... rigorous and statin intervention was highly variable in this small number of studies. This systematic review demonstrates that there is a significant gap that exists in the current literature in regards to the potential anti–inflammatory effect of statin therapy prior to CPB.
[more...]
|
The SLCO1B1*5 Genetic Variant Is Associated With Statin-Induced Side Effects
JACC - Journal of the American College of Cardiology, 10/19/2009
|
Voora D et al. – SLCO1B1*5 genotype and female sex were associated mild statin–induced side effects. These findings expand the results of a recent genome–wide association study of statin myopathy with CK >3x normal to milder, statin–induced
[more...]
|
The effect of statin therapy on the progression of carotid artery stenosis in relation to stenosis severity
Acta Neurologica Scandinavica, 11/19/2009
|
Hegland O et al. – The aim is to examine the effect of early statin treatment on progression of arteriosclerosis in internal carotid arteries (ICA); to compare the progression of ... ICA of patients treated with a statin to the progression seen in drug–naive patients. Treatment with statins already in early stages of ICA stenosis might delay the progression and even reverse the degree of stenosis.
[more...]
|
